Sanaa Tahiri

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

Anne M. Noonan, Matthew R. Farren, Susan Geyer et al. · Molecular Therapy · 2016 · 161 citations · Full text

Medicine, Oncology, Pharmacology +17

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Andrew H. Ko, Tanios Bekaii‐Saab, Jessica Van Ziffle et al. · Clinical Cancer Research · 2015 · 121 citations · Full text

Medicine, Oncology, Pharmacology +14

Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer

Matthew R. Farren, Thomas A. Mace, Susan Geyer et al. · Clinical Cancer Research · 2015 · 110 citations · Full text

Medicine, Immunology, Oncology +17

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher et al. · Cancer Chemotherapy and Pharmacology · 2013 · 54 citations

Medicine, Oncology, Pharmacology +8

Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.

Deirdre Jill Cohen, Paul J. Christos, Hedy L. Kindler et al. · Journal of Clinical Oncology · 2013 · 36 citations

Medicine, Oncology, Pharmacology +17